Collectively, these findings suggest that SPARC is a pivotal downstream target of the LCN2/24p3R/JNK/c-Jun axis, and is also a necessary and sufficient key oncogenic driver of GC progression. The gene discussed is LCN2; the disease is gastric cancer.